Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17314517 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3GPR119HSD17B10 | |
| SCHEMBL29183836 | 0.84 | TSHR (0.43) | CHRM2CHRM1CHRM3GPR119HSD17B10 | |
| SCHEMBL13634174 | 0.84 | TSHR (0.43) | CHRM2CHRM1CHRM3GPR119HSD17B10 | |
| SCHEMBL20707140 | 0.84 | TSHR (0.43) | CHRM2CHRM1CHRM3GPR119HSD17B10 | |
| SCHEMBL18710762 | 0.84 | TSHR (0.43) | CHRM2CHRM1CHRM3GPR119HSD17B10 | |
| SCHEMBL23492915 | 0.84 | GPR119 (0.38) | CHRM2CHRM1CHRM3GPR119HSD17B10 | |
| SCHEMBL24603315 | 0.83 | TSHR (0.50) | EPHX1 | |
| SCHEMBL1549880 | 0.82 | CHRM2 (0.40) | CHRM2CHRM1CHRM3GPR119HSD17B10 | |
| SCHEMBL2544292 | 0.82 | CHRM2 (0.40) | CHRM2CHRM1CHRM3GPR119HSD17B10 | |
| SCHEMBL2536245 | 0.82 | CHRM2 (0.40) | CHRM2CHRM1CHRM3GPR119HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2951180-B1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9540377-B2 | 2,6,7,8 substituted purines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150353553-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353553-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | DDX21, DPYD, NSUN2 | CHRM2 4830/4885CHRM1 4854/4885CHRM3 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.